Perrigo Company plc - Form 8-K Summary
Business Context and Reporting Period
Perrigo Company plc (PRGO), a global pharmaceutical company incorporated in Ireland, filed this Current Report on Form 8-K on March 1, 2022. The filing serves to announce the release of earnings results for the fourth quarter and full year ended December 31, 2021. The detailed financial data is contained in the attached press release (Exhibit 99.1), which is not included in the text of this filing.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It references the existence of these metrics in the attached press release but does not disclose them directly.
The Company reports both GAAP and non-GAAP financial measures. Non-GAAP measures exclude items such as:
- Amortization expense related to acquired intangible assets.
- Acquisition and integration-related charges and contingent consideration adjustments.
- Impairment charges and restructuring charges.
- Unusual litigation and separation/reorganization expenses.
- Foreign currency translation movements.
- Specific acquisition impacts (e.g., Eastern European Brands, Dr. Fresh) and divestitures (e.g., Rosemont Rx).
Material Changes and Adjustments
The filing outlines the specific adjustments made to derive non-GAAP results for the three and twelve months ended December 31, 2021, compared to the prior year periods. Key adjustments impacting comparability include:
- 2021 Adjustments: Inclusion of net sales from the Eastern European Brands acquisition and Dr. Fresh acquisition, alongside standard exclusions for amortization, restructuring, and litigation.
- 2020 Adjustments: Exclusions for the Rosemont Pharmaceuticals net sales (divested business), loss on early debt extinguishment, and indirect RX business support costs.
Organic net sales growth is calculated by excluding the impacts of the Dr. Fresh and Eastern European Brands acquisitions, the divested Rosemont Rx liquids business, and currency fluctuations.
Management Commentary and Outlook
Management utilizes non-GAAP measures to evaluate ongoing operating trends, facilitate peer comparisons, and assess future performance prospects. These adjusted measures are also used for planning, forecasting, and determining executive compensation. The filing emphasizes that non-GAAP measures should be considered in conjunction with, not as a substitute for, GAAP financial statements.
The filing does not contain specific forward-looking guidance, risk factors, or contingency details beyond the standard disclosure that the report is not "filed" for liability purposes under Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific GAAP and non-GAAP revenue, net income, and EPS figures for Q4 and FY 2021.
- Verify the reconciliation table between GAAP and non-GAAP results to understand the magnitude of excluded items like amortization and restructuring charges.
- Confirm the specific impact of the Dr. Fresh and Eastern European Brands acquisitions on reported sales growth.
- Check the full 10-K or 10-Q filings for detailed debt covenants, liquidity positions, and comprehensive risk factors not detailed in this 8-K.